CITIUS PHARMACEUTICALS INC (CTXR)
NASDAQHealth CareBiotechnologySnapshot 2026-11-04
$0.56+1.16%
Close 2026-11-05 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-11-04
QuarterlyIQ Insights · CTXR
What must go right, what could break, what the price assumes, and what evidence comes next.
The current health of the standing investment case.
Recent financial performance sits well below its industry cohort — worth keeping an eye on, though it has not freshly broken.
One-year growth currently built into the price, compared with our model's estimate.
| Measure | Marker shape | Value |
|---|---|---|
| Growth built into the price | circle | -85.3% |
| Our one-year growth estimate | diamond | Not available |
Growth built into the price is above our model estimate.
For each item: what to watch, what would become a concern, and what would make it less concerning.
A reporting-risk estimate, not a forecast of the stock-price response.
Historical relationships that met the evidence threshold. They do not prove cause or forecast a move.
Usually moved in the same direction.
Price observations: 365 days
Most sensitive to the broad stock market.
Based on historical daily prices through 2026-11-04.
Past price behavior in dollars on a $10,000 position. This does not measure permanent business risk.
How much price usually moves either way.
Use the underlying financial and sector pages to investigate the cause.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
A comparable growth gap is not available.
The one-year revenue growth assumption on Valuation.
Elevated risk of a next-quarter earnings miss: this name has been missing across recent quarters and is a smaller-cap name (higher miss base rate). A fundamental tilt, not a price call.
Model as of 2026-11-04 · Compared with 66 industry peers
CTXR — earnings miss
Dated 2026-10-26
Results of Operations and Financial Condition. On October 26, 2026, our wholly-owned subsidiary, Citius Oncology, Inc., issued a press release announcing preliminary, unaudited LYMPHIR ® (denileukin diftitox-cxdl) unit sales to U.S. wholesalers and institutional vial orders for the fiscal fourth quarter ended September 30, 2026. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K. The information in this Item 2.02 (including Exhibit 99.1) shall not be d…
Why it matters: Wholesaler sales rose, but these figures are preliminary. Final revenue will show how much of the rise reached reported sales.
Watch forThe FY2026 report confirms at least 792 LYMPHIR units sold to wholesalers in Q4. It shows no major cut to the early figure.
Also watch forThe FY2026 report shows fewer than 792 units sold to wholesalers in Q4, or a major drop in Q4 revenue from Q3's $1.5 million.
Why it matters: CTXR reported $17.0 million in cash at June 30 and used $23.0 million in operating cash over nine months. New funds or a clear cash runway matter to ongoing work.
Worry ifThe December results show cash above $17.0 million, or report new funding for at least 12 months of operations.
Less concerning ifThe December results show cash below $17.0 million with no new funding, or say funds may not cover 12 months of operations.
A larger daily loss that occurred about once in every 20 trading days.
Deepest peak-to-trough drop in the last year.
| Measure | Value | Meaning |
|---|---|---|
| Typical day | ±$395 on $10,000 · ±4.0% | How much price usually moves either way. |
| Bad day | $893 loss on $10,000 · 8.9% | A larger daily loss that occurred about once in every 20 trading days. |
| Largest peak-to-trough drop in the past year | $7,425 loss on $10,000 · 74.3% | Deepest peak-to-trough drop in the last year. |
Past year. 1.00 means similar movement; 1.20 means about 20% more.
Past year. 1.00 means similar movement to the sector. This is secondary context.
Latest 30 trading days, shown as an annual percentage.
Latest 252 trading days, shown as an annual percentage.
20-trading-day average in US dollars.
Trading days used by the source risk snapshot.
Past results, not a forecast. Not investment advice.